404 related articles for article (PubMed ID: 16601572)
1. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide.
Landmesser U; Drexler H
J Hypertens Suppl; 2006 Mar; 24(1):S39-43. PubMed ID: 16601572
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G
Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975
[TBL] [Abstract][Full Text] [Related]
3. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure.
Hornig B; Arakawa N; Drexler H
Eur Heart J; 1998 Jul; 19 Suppl G():G48-53. PubMed ID: 9717056
[TBL] [Abstract][Full Text] [Related]
4. Endothelial function and dysfunction in heart failure.
Ferrari R; Bachetti T; Agnoletti L; Comini L; Curello S
Eur Heart J; 1998 Jul; 19 Suppl G():G41-7. PubMed ID: 9717055
[TBL] [Abstract][Full Text] [Related]
5. ACE inhibitor and AT1 antagonist stimulate duodenal HCO3- secretion mediated by a common pathway - involvement of PG, NO and bradykinin.
Aihara E; Kagawa S; Hayashi M; Takeuchi K
J Physiol Pharmacol; 2005 Sep; 56(3):391-406. PubMed ID: 16204762
[TBL] [Abstract][Full Text] [Related]
6. Endothelial function and bradykinin in humans.
Hornig B; Drexler H
Drugs; 1997; 54 Suppl 5():42-7. PubMed ID: 9429844
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting enzyme inhibitors: role of bradykinin generation during ACE inhibition.
Mombouli JV; Vanhoutte PM
J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S74-82. PubMed ID: 1282634
[TBL] [Abstract][Full Text] [Related]
8. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin.
Nagai N; Oike Y; Izumi-Nagai K; Koto T; Satofuka S; Shinoda H; Noda K; Ozawa Y; Inoue M; Tsubota K; Ishida S
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2321-6. PubMed ID: 17460297
[TBL] [Abstract][Full Text] [Related]
9. [Endothelial mechanisms in vasomotor effects of ACE inhibitors].
Busse R; Hecker M
Z Kardiol; 1994; 83 Suppl 4():1-6. PubMed ID: 7856274
[TBL] [Abstract][Full Text] [Related]
10. Local regulation of vascular tone by bradykinin and angiotensin converting enzyme inhibitors.
Auch-Schwelk W; Kuchenbuch C; Claus M; Walther B; Bossaller C; Friedel N; Graf K; Gräfe M; Fleck E
Eur Heart J; 1993 Nov; 14 Suppl I():154-60. PubMed ID: 8293767
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II type 1 receptor antagonism improves endothelial vasodilator function in L-NAME-induced hypertensive rats by a kinin-dependent mechanism.
De Gennaro Colonna V; Fioretti S; Rigamonti A; Bonomo S; Manfredi B; Muller EE; Berti F; Rossoni G
J Hypertens; 2006 Jan; 24(1):95-102. PubMed ID: 16331106
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II-induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide.
Yayama K; Okamoto H
Int Immunopharmacol; 2008 Feb; 8(2):312-8. PubMed ID: 18182246
[TBL] [Abstract][Full Text] [Related]
13. An AT1-receptor antagonist and an angiotensin-converting enzyme inhibitor protect against hypoxia-induced apoptosis in human aortic endothelial cells through upregulation of endothelial cell nitric oxide synthase activity.
Matsumoto N; Manabe H; Ochiai J; Fujita N; Takagi T; Uemura M; Naito Y; Yoshida N; Oka S; Yoshikawa T
Shock; 2003 Jun; 19(6):547-52. PubMed ID: 12785010
[TBL] [Abstract][Full Text] [Related]
14. Blockade of endothelial enzymes: new therapeutic targets.
López-Jaramillo P; Casas JP
J Hum Hypertens; 2002 Mar; 16 Suppl 1():S100-3. PubMed ID: 11986905
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibitors unmask endogenous kinin production by bovine coronary artery endothelium.
Hecker M; Bara AT; Busse R
Eur Heart J; 1993 Nov; 14 Suppl I():161-3. PubMed ID: 8293768
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of ACE inhibitors versus AT1 blockers.
Vaughan D
Can J Cardiol; 2000 Aug; 16 Suppl E():36E-40E. PubMed ID: 10906625
[TBL] [Abstract][Full Text] [Related]
17. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
Enseleit F; Hürlimann D; Lüscher TF
J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
[TBL] [Abstract][Full Text] [Related]
18. ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide.
Mombouli JV
Drugs; 1997; 54 Suppl 5():12-22. PubMed ID: 9429841
[TBL] [Abstract][Full Text] [Related]
19. Bradykinin as a major endogenous regulator of endothelial function.
Gryglewski RJ; Uracz W; Chłopicki S; Marcinkiewicz E
Pediatr Pathol Mol Med; 2002; 21(3):279-90. PubMed ID: 12056503
[TBL] [Abstract][Full Text] [Related]
20. Effects of converting enzyme inhibition on endothelial bradykinin metabolism and endothelium-dependent vascular relaxation.
Bossaller C; Auch-Schwelk W; Gräfe M; Graf K; Baumgarten C; Fleck E
Agents Actions Suppl; 1992; 38 ( Pt 3)():171-7. PubMed ID: 1334349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
